Meeting News Coverage

Anti-VEGF superior to laser at 24 weeks for BRVO

ORLANDO, Fla. — A study here showed aflibercept to have superior efficacy and safety compared with grid laser photocoagulation at 24 weeks, according to the poster’s author.

“The VIBRANT study showed the safety and efficacy of intravitreal aflibercept injections for the treatment of macular edema secondary to branch retinal vein occlusion,” David S. Boyer, MD, told Ocular Surgery News at the Association for Research in Vision and Ophthalmology meeting.

The VIBRANT study was a randomized, multicenter, double-masked trial of 183 patients with macular edema secondary to BRVO. Patients were randomized one to one, with 92 receiving laser treatment and 91 receiving intravitreal injections of Eylea (aflibercept, Regeneron) every 4 weeks.

“Unlike other studies,” Boyer said, “such as the BRAVO study that had a sham comparator, this actually had an active arm of laser compared to 2 mg of aflibercept given every 4 weeks.”

Laser re-treatment was permitted under certain conditions, according to Boyer.

“So over a 24-week period, there was about a 10-letter difference of 17 vs. 6.9, between the laser group and the aflibercept-treated group,” he said. “This also corresponds to central retinal thickness. It was also manifest in the VFQ scores.”

The mean number of injections in the study was 5.7 at week 24, compared with 1.7 laser treatments, according to the poster.

Disclosure: Boyer has received honoraria or travel grants from Regeneron.

ORLANDO, Fla. — A study here showed aflibercept to have superior efficacy and safety compared with grid laser photocoagulation at 24 weeks, according to the poster’s author.

“The VIBRANT study showed the safety and efficacy of intravitreal aflibercept injections for the treatment of macular edema secondary to branch retinal vein occlusion,” David S. Boyer, MD, told Ocular Surgery News at the Association for Research in Vision and Ophthalmology meeting.

The VIBRANT study was a randomized, multicenter, double-masked trial of 183 patients with macular edema secondary to BRVO. Patients were randomized one to one, with 92 receiving laser treatment and 91 receiving intravitreal injections of Eylea (aflibercept, Regeneron) every 4 weeks.

“Unlike other studies,” Boyer said, “such as the BRAVO study that had a sham comparator, this actually had an active arm of laser compared to 2 mg of aflibercept given every 4 weeks.”

Laser re-treatment was permitted under certain conditions, according to Boyer.

“So over a 24-week period, there was about a 10-letter difference of 17 vs. 6.9, between the laser group and the aflibercept-treated group,” he said. “This also corresponds to central retinal thickness. It was also manifest in the VFQ scores.”

The mean number of injections in the study was 5.7 at week 24, compared with 1.7 laser treatments, according to the poster.

Disclosure: Boyer has received honoraria or travel grants from Regeneron.

    See more from Association for Research in Vision and Ophthalmology